Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 8/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20070364 | 0.89 | RET (0.41) | RETKDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL20158490 | 0.87 | RET (0.41) | RETKDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL20147896 | 0.85 | RET (0.45) | RETKDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL20147519 | 0.85 | RET (0.40) | RETKDM4ESMN1; SMN2 | |
| SCHEMBL20070365 | 0.78 | RET (0.43) | RETSMN1; SMN2MEN1KMT2A | |
| SCHEMBL20147522 | 0.75 | RET (0.41) | RETSMN1; SMN2MEN1KMT2A | |
| SCHEMBL20069522 | 0.74 | RET (0.43) | RETSMN1; SMN2MEN1KMT2A | |
| SCHEMBL20069520 | 0.74 | RET (0.43) | RETKDM4ESMN1; SMN2EPHX1MEN1 | |
| SCHEMBL20070368 | 0.73 | RET (0.44) | RETKDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL20070369 | 0.73 | RET (0.44) | RETKDM4ESMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | RET 1/4885KDM4E 547/4885SMN1; SMN2 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.